News | Nuclear Imaging | November 07, 2018

New market report notes that approximately $10 billion in M&A transactions have occurred over the past four years, with signs indicating continuing future growth

MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine

November 7, 2018 — With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry towards radiopharmaceuticals and in particular radiotherapeutics and radiotheranostics is clearly growing, as foreseen a few years ago by MEDraysintell.

Numerous major acquisitions have involved the conventional pharmaceutical industry over the past four years:

  • In 2014, Bayer acquired Algeta ASA and its major drug for end-stage prostate cancer treatment 223Ra-Xofigo for about NOK 17.6 billion ($2.9 billion), while Novartis took over Advanced Accelerator Applications (AAA) and its Neuro Endocrine Tumor treatment 177Lu-Lutathera in January 2018 for a total value of $3.9 billion;
  • Additionally Novartis announced in October 2018 the acquisition of the company Endocyte developing the prostate cancer drug 177Lu-PSMA-617 for a total value of $2.1 billion. This transaction is expected to be completed in the first half of 2019.
  • Ipsen Pharma acquired in May 2015 the German company OctreoPharm Sciences GmbH, for a total of EUR 50 million (about $55 million) and one year later a large part of the radiopharmaceutical pipeline of the German company 3B Pharmaceuticals GmbH; and
  • Sun Pharmaceutical Industries acquired Pharmalucence in July 2014 for an undisclosed amount.

MEDraysintell noted that other mergers within the radiopharmaceutical industry showed consolidation of this industry:

  • IBA Molecular acquired the Nuclear Medicine business of Mallinckrodt in January 2017 for a total of about $690 million;
  • Jubilant Draximage acquired the Triad Isotopes radiopharmacy network in May 2017; and
  • Sofie Biosciences took over Zevacor Pharma in May 2017.

The company said there are great chances that additional mergers and acquisitions (M&A) will take place within the next 12 months. At the same time, the conventional pharmaceutical industry is now looking for new opportunities in early-stage research programs in this area. MEDraysintell anticipates that the global market will reach $5.9 billion in 2019, and it is now expected that radiotherapeutics will represent more than 60 percent of the $26 billion nuclear medicine market by 2030.

Most of the development of new radiopharmaceuticals is performed by new medium-sized radiopharmaceuticals companies and conventional pharmaceutical corporations. MEDraysintell said these companies are extensively covered in the new Nuclear Medicine Report & Directory, Edition 2018.

For more information: www.medraysintell.com

Related Content

Feature | Nuclear Imaging

The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics (SPECT, PET)), Therapeutics ...

Time May 26, 2022
arrow
News | Proton Therapy

May 25, 2022 — B dot Medical Inc. and Research Center for Nuclear Physics, Osaka University (RCNP) have conducted a ...

Time May 25, 2022
arrow
News | Contrast Media

May 19 2022 — Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare ...

Time May 19, 2022
arrow
News | Contrast Media

May 18, 2022 —According to ARRS’ American Journal of Roentgenology (AJR), to ensure that patients with emergent or life ...

Time May 18, 2022
arrow
News | Radiopharmaceuticals and Tracers

May 16, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 16, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

May 13, 2022 — Alzheimer’s disease is the most common form of dementia, one of the major causes of dependency and ...

Time May 13, 2022
arrow
News | Contrast Media

May 13, 2022 — The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware ...

Time May 13, 2022
arrow
News | Nuclear Imaging

May 9, 2022 — Novartis announced a temporary, voluntary suspension of production at its radioligand therapy production ...

Time May 09, 2022
arrow
News | Proton Therapy

May 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time May 05, 2022
arrow
News | Coronavirus (COVID-19)

May 4, 2022 — While the COVID-19 pandemic transitions through various phases, nuclear cardiology teams should maintain a ...

Time May 04, 2022
arrow
Subscribe Now